392 related articles for article (PubMed ID: 26449481)
21. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
Pilgrim T; Vranckx P; Valgimigli M; Stefanini GG; Piccolo R; Rat J; Rothenbühler M; Stortecky S; Räber L; Blöchlinger S; Hunziker L; Silber S; Jüni P; Serruys PW; Windecker S
Am Heart J; 2016 May; 175():56-65. PubMed ID: 27179724
[TBL] [Abstract][Full Text] [Related]
22. Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions.
Dean BB; Yu HT; Bae JP; Fiske S; Meadows E; Xiong Y; Emons MF
Am J Health Syst Pharm; 2010 Sep; 67(17):1430-7. PubMed ID: 20720242
[TBL] [Abstract][Full Text] [Related]
23. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Wiviott SD; White HD; Ohman EM; Fox KA; Armstrong PW; Prabhakaran D; Hafley G; Lokhnygina Y; Boden WE; Hamm C; Clemmensen P; Nicolau JC; Menozzi A; Ruzyllo W; Widimsky P; Oto A; Leiva-Pons J; Pavlides G; Winters KJ; Roe MT; Bhatt DL
Lancet; 2013 Aug; 382(9892):605-13. PubMed ID: 23953385
[TBL] [Abstract][Full Text] [Related]
24. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
25. Managing acute coronary syndrome: evidence-based approaches.
Spinler SA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441
[TBL] [Abstract][Full Text] [Related]
26. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
[TBL] [Abstract][Full Text] [Related]
27. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
[TBL] [Abstract][Full Text] [Related]
28. [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
Silber S
Herz; 2010 Dec; 35(8):558-64. PubMed ID: 21107514
[TBL] [Abstract][Full Text] [Related]
29. Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Duggan ST; Keating GM
Drugs; 2009 Aug; 69(12):1707-26. PubMed ID: 19678718
[TBL] [Abstract][Full Text] [Related]
30. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
Bonello L; Berbis J; Laine M; Armero S; Bessereau J; Jacquin L; Bonello C; Camillieri E; Barragan P; Dignat-George F; Paganelli F; Camoin-Jau L
Thromb Haemost; 2012 Jul; 108(1):101-6. PubMed ID: 22535315
[TBL] [Abstract][Full Text] [Related]
31. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Zhao Z; Wang J; Lei M; Li Y; Yang Y; An L; Sun X; Li C; Xue Z
BMC Cardiovasc Disord; 2023 Mar; 23(1):168. PubMed ID: 36991321
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial).
Patti G; Pasceri V; Mangiacapra F; Colonna G; Vizzi V; Ricottini E; Montinaro A; D'Ambrosio A; Wijns W; Barbato E; Di Sciascio G;
Am J Cardiol; 2013 Jul; 112(2):162-8. PubMed ID: 23601577
[TBL] [Abstract][Full Text] [Related]
34. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
Dangas G; Mehran R; Guagliumi G; Caixeta A; Witzenbichler B; Aoki J; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Rabbani LE; Parise H; Stone GW;
J Am Coll Cardiol; 2009 Oct; 54(15):1438-46. PubMed ID: 19796737
[TBL] [Abstract][Full Text] [Related]
35. [Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
De Luca L; Pennacchi M; Musumeci G; D'Ascenzo F; Gallo P; Rigattieri S; Granatelli A; Berti S; Gulizia MM; De Servi S; Bolognese L;
G Ital Cardiol (Rome); 2018 Feb; 19(2):101-110. PubMed ID: 29531382
[TBL] [Abstract][Full Text] [Related]
36. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
37. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
[TBL] [Abstract][Full Text] [Related]
38. Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.
Romppanen H; Nammas W; Kervinen K; Mikkelsson J; Pietilä M; Lalmand J; Rivero-Crespo F; Pentikäinen M; Tedjokusumo P; Karjalainen PP
Minerva Cardioangiol; 2013 Apr; 61(2):201-9. PubMed ID: 23492603
[TBL] [Abstract][Full Text] [Related]
39. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of clopidogrel in acute coronary syndrome.
Zambahari R; Kwok OH; Javier S; Mak KH; Piyamitr S; Tri Ho HQ; Hwang JJ; Suryawan R; Chow WH
Int J Clin Pract; 2007 Mar; 61(3):473-81. PubMed ID: 17313616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
